Sandra Moser

In addition to her background representing clients in complex financial and healthcare frauds, Sandra focuses on matters related to the Foreign Corrupt Practices Act (FCPA), the False Claims Act (FCA), securities, commodities, and anti-money laundering. She also handles corporate investigations and crisis management.

Sandra focuses on results for clients, whether they be large public companies or individuals under scrutiny. She has obtained declinations from multiple sections of the DOJ’s Criminal and Civil Divisions in FCPA, fraud, crypto, FCA, and healthcare-related cases, and obtained similar favorable results from the SEC, the CFTC, and the UK Serious Fraud Office.

As chief of the DOJ’s Fraud Section, Sandra led a team of 150-plus white collar prosecutors and oversaw the FCPA Unit, as well as the section’s healthcare, securities, and financial fraud prosecutions. She led, negotiated, or approved dozens of corporate enforcement resolutions, including global coordinated resolutions involving multiple domestic and foreign authorities, and played a key role in the selection and oversight of corporate monitors. She currently serves as the co-chair of the Women in White Collar Defense Association’s Monitor Committee.  

Sandra also helped develop and implement significant policy changes affecting corporate criminal enforcement throughout the DOJ, including the Corporate Enforcement Policy and various reforms to the Justice Manual.

Sandra speaks across the United States and abroad at forums addressing enforcement policies, trends, and priorities in the white collar space. She also guest lectures at academic institutions, including Harvard Law School, Harvard Business School, and the University of Pennsylvania Carey Law School.

Before joining Morgan Lewis, Sandra was a partner at another global law firm, where she co-chaired the investigations, government enforcement, and white collar criminal defense practice.

• A multinational conglomerate in an FCPA investigation before the DOJ and SEC 
• An exchange in a market manipulation investigation before the DOJ and CFTC
• A global bank in a financial fraud investigation before the DOJ, CFTC, and SEC
• A media company in an FCPA investigation before the DOJ and SEC 
• A pharmaceutical company in connection with a DOJ investigation 
• An institutional pharmacy in an FCA investigation before the DOJ 
• An automotive technology supplier in an FCA investigation before the DOJ
• Pre-investment and pre-acquisition enhanced FCPA/anti-corruption due diligence in numerous significant deals
• Numerous companies, from startups to Fortune 50 corporations, in assisting with drafting codes of conduct and compliance procedures; conducting risk assessments, gap analysis, and compliance benchmarking; and enhancing existing compliance programs 
• A former White House employee in an investigation by the House Committee on the Judiciary
• A former investor relations executive of a public company before the SEC in an accounting fraud investigation 
• A pharmaceutical company executive in connection with an SEC investigation
• A publicly traded company in connection with a Federal Trade Commission investigation
• As head of the DOJ Fraud Section, approval and hands-on responsibility for all corporate enforcement action, significant individual charging decisions and litigation strategy
• One of the lead lawyers for the United States in the LIBOR investigation for manipulation of the benchmark interest rate resulting in a myriad of corporate enforcement actions and individual charges
• Prosecution of a financial institution CEO for securities fraud; convicted after a jury trial in 2016
• One of the lead trial lawyers for the United States in the investigation and prosecution of more than 40 individuals arrested in connection with political corruption, rabbinical money laundering, and black market organ sales in New Jersey and New York

Results may vary depending on your particular facts and legal circumstances.